Ciglitazone
| Code | Size | Price |
|---|
| TAR-T19710-5mg | 5mg | £144.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Ciglitazone is a PPARγ agonist. It decreases insulin levels, VEGF production, and blood pressure and induces cell cycle arrest in stomach cancer cells.
CAS:
74772-77-3
Formula:
C18H23NO3S
Molecular Weight:
333.45
Pathway:
DNA Damage/DNA Repair|Apoptosis|MAPK|Metabolism
Purity:
0.98
SMILES:
CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1
Target:
p38 MAPK|PPAR|Apoptosis
References
1. Shin SJ, Kim JY, Kwon SY, Mun KC, Cho CH, Ha E. Ciglitazone enhances ovarian cancer cell death via inhibition of glucose transporter-1. Eur J Pharmacol. 2014 Nov 15;743:17-23. doi: 10.1016/j.ejphar.2014.09.013. Epub 2014 Sep 21. PubMed PMID: 25240713.
2. Xu L, Wang S, Li B, Sun A, Zou Y, Ge J. A protective role of ciglitazone in ox-LDL-induced rat microvascular endothelial cells via modulating PPAR?-dependent AMPK/eNOS pathway. J Cell Mol Med. 2015 Jan;19(1):92-102. doi: 10.1111/jcmm.12463. Epub 2014 Nov 11. PubMed PMID: 25388834; PubMed Central PMCID: PMC4288353.
3. Hann SS, Tang Q, Zheng F, Zhao S, Chen J, Wang Z. Repression of phosphoinositide-dependent protein kinase 1 expression by ciglitazone via Egr-1 represents a new approach for inhibition of lung cancer cell growth. Mol Cancer. 2014 Jun 13;13:149. doi: 10.1186/1476-4598-13-149. PubMed PMID: 24925061; PubMed Central PMCID: PMC4061523.
4. Otto S, Jaeger K, Kolodgie FD, Muehlstaedt D, Franz M, Bischoff S, Schubert H, Figulla HR, Virmani R, Poerner TC. A novel polymer-free ciglitazone-coated vascular stent: in vivo and ex vivo analysis of stent endothelialization in a rabbit iliac artery model. Oncotarget. 2016 Sep 6;7(36):57571-57580. doi: 10.18632/oncotarget.11584. PubMed PMID: 27613845; PubMed Central PMCID: PMC5295373.